The Food and Drug Administration silenced one of its drug experts whoraised safety concerns weeks before Merck &amp; Co. yanked theblockbuster drug Vioxx due to increased risks for heart attack andstrokes, the chairman of the Senate Finance Committee said Thursday. 
Seven weeks before Merck &amp; Co. pulled the arthritis drug Vioxxoff the market because of safety concerns, federal drug regulatorsdownplayed the significance of scientific findings citing theincreased risks, documents released Thursday show. 
Less than a week after Merck &amp; Co. yanked its popular Vioxxarthritis drug off the market, the New England Journal of Medicinevoiced strong concerns Wednesday about the safety